The 26 most recent market catalysts affecting $GH, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 9, 2026
Corporate Catalyst
Bullish
Impact 55
UBS Maintains Buy on Guardant Health, Raises Price Target to $225
UBS analyst Dan Leonard has maintained a 'Buy' rating on Guardant Health and significantly raised the price target from $175 to $225. This action signals strong conviction from a p…
Sep 8, 2026
Corporate Catalyst
Neutral
Impact 65
Rothschild & Co Initiates Coverage On Guardant Health with Buy Rating, Announces Price Target of $203
Rothschild & Co's initiation of coverage on Guardant Health with a 'Buy' rating and a $203 price target is a positive development for the company. Analyst coverage, especially with…
Sep 8, 2026
Corporate Catalyst
Bullish
Impact 92
Guardant Health shares are trading higher after the company announced the FDA approved Guardant360 CDx.
The FDA approval of Guardant360 CDx is a major positive catalyst for Guardant Health (GH). This regulatory milestone validates their liquid biopsy technology for comprehensive geno…
Sep 7, 2026
Corporate Catalyst
Bullish
Impact 75
Reported Earlier, Guardant Health Said The FDA Approved Guardant360 CDx As A Companion Diagnostic To Identify HR-positive, HER2-negative Advanced Or Metastatic Breast Cancer Patients With ESR1 Mutations Who May Benefit From Astrazeneca’s ETCAMAH (Camizestrant)
This FDA approval is a positive catalyst for both Guardant Health and AstraZeneca. For Guardant Health, it validates their Guardant360 CDx as a crucial companion diagnostic, openin…
Sep 2, 2026
Corporate Catalyst
Neutral
Impact 55
BTIG Reiterates Buy on Guardant Health, Maintains $195 Price Target
BTIG analyst Mark Massaro has reaffirmed a 'Buy' rating and a $195 price target for Guardant Health. This action signals that the analyst's investment thesis for GH remains unchang…
Sep 1, 2026
Corporate Catalyst
Bullish
Impact 85
Guardant Health shares are trading higher after the company announced that its Shield blood test for colorectal cancer screening will be covered in Carelon Healthcare Services clinical guidelines.
This news is a significant positive catalyst for Guardant Health. Inclusion in Carelon Healthcare Services' clinical guidelines means a substantial increase in the addressable mark…
Sep 1, 2026
Corporate Catalyst
Bullish
Impact 75
Carelon Health Services To Cover Guardant Health’s Shield Blood Test
Guardant Health announced that Carelon Health Services, a major medical benefit manager, will now cover its FDA-approved Shield blood test for colorectal cancer screening. This is …
Aug 24, 2026
Corporate Catalyst
Bearish
Impact 75
Guardant Health Announces Appeal Of Delaware District Court Final Judgment In TwinStrand Patent Suit, With Execution And Royalty Collection Stayed Pending Appeal
This headline signals a significant corporate catalyst for Guardant Health. While the initial judgment was negative, the appeal and stay on execution provide a temporary reprieve, …
Aug 24, 2026
Corporate Catalyst
Bearish
Impact 85
Guardant Health Hit With Ongoing Royalties Over Duplex Sequencing Tech
Guardant Health has been hit with a substantial financial penalty of over $245.2 million for willful infringement of Duplex Sequencing patents, cementing a November 2023 jury verdi…
Aug 24, 2026
Corporate Catalyst
Bearish
Impact 85
Guardant Health shares are trading lower after the U.S. District Court for the District of Delaware ruled in favor of TwinStrand and the University of Washington in their patent infringement lawsuit against the company.
The U.S. District Court ruling against Guardant Health in a patent infringement lawsuit is a significant corporate catalyst. This directly impacts GH's intellectual property, which…
Aug 4, 2026
Corporate Catalyst
Bullish
Impact 65
Piper Sandler Maintains Overweight on Guardant Health, Raises Price Target to $193
Piper Sandler analyst David Westenberg maintained an Overweight rating on Guardant Health (GH) and raised the price target from $135 to $193. This substantial increase in the price…
Aug 4, 2026
Corporate Catalyst
Bullish
Impact 65
Stephens & Co. Maintains Overweight on Guardant Health, Raises Price Target to $195
Stephens & Co. analyst Mason Carrico's decision to maintain an 'Overweight' rating on Guardant Health (GH) and raise the price target from $170 to $195 signals a strong vote of con…
Aug 4, 2026
Corporate Catalyst
Bullish
Impact 60
Morgan Stanley Maintains Overweight on Guardant Health, Raises Price Target to $185
Morgan Stanley analyst Shannon O'Callaghan maintained an 'Overweight' rating on Guardant Health (GH) and raised the price target from $175 to $185. This action signals a positive o…
Aug 3, 2026
Corporate Catalyst
Bullish
Impact 65
Stifel Maintains Buy on Guardant Health, Raises Price Target to $180
Stifel analyst Daniel Arias maintained a 'Buy' rating on Guardant Health (GH) and raised the price target from $130 to $180. This substantial increase in the price target, a 38.5% …
Jul 31, 2026
Corporate Catalyst
Bullish
Impact 65
RBC Capital Maintains Outperform on Guardant Health, Raises Price Target to $200
RBC Capital analyst Dan Leonard has maintained an 'Outperform' rating on Guardant Health (GH) and raised the price target from $185 to $200. This action signals a continued positiv…
Jul 31, 2026
Corporate Catalyst
Bullish
Impact 65
Mizuho Maintains Outperform on Guardant Health, Raises Price Target to $200
Mizuho analyst Anthony Petrone maintained an 'Outperform' rating on Guardant Health and raised the price target from $175 to $200. This indicates a strong belief in the company's g…
Jul 31, 2026
Corporate Catalyst
Bullish
Impact 65
JP Morgan Maintains Overweight on Guardant Health, Raises Price Target to $195
JP Morgan's analyst Casey Woodring maintained an 'Overweight' rating on Guardant Health (GH) and raised the price target from $185 to $195. This indicates a positive outlook from a…
Jul 31, 2026
Corporate Catalyst
Bullish
Impact 55
TD Cowen Maintains Buy on Guardant Health, Raises Price Target to $210
TD Cowen analyst Dan Brennan maintained a 'Buy' rating on Guardant Health and raised the price target from $200 to $210. This action signals a continued bullish outlook from a prom…
Jul 31, 2026
Corporate Catalyst
Bullish
Impact 85
Guardant Health shares are trading higher after the company reported better-than-expected Q2 sales results and raised its FY26 sales guidance above estimates. Also, BTIG raised its price target on the stock from $190 to $195.
This headline represents a significant positive corporate catalyst for Guardant Health. Better-than-expected Q2 sales and a raised FY26 sales guidance signal strong operational per…
Jul 31, 2026
Corporate Catalyst
Bullish
Impact 55
BTIG Maintains Buy on Guardant Health, Raises Price Target to $195
BTIG analyst Mark Massaro has maintained a 'Buy' rating on Guardant Health (GH) and raised the price target from $190 to $195. This action signals continued bullish sentiment from …
Jul 30, 2026
Corporate Catalyst
Neutral
Impact 55
Guardant Health Files Shelf Prospectus For Offering; Size Not Disclosed
Guardant Health filed an 8-K disclosing a shelf prospectus. This is a standard regulatory filing that allows a company to register a variety of securities (like common stock, prefe…
Jul 30, 2026
Corporate Catalyst
Bullish
Impact 85
Guardant Health shares are trading higher after the company reported better-than-expected Q2 sales results and raised its FY26 sales guidance above estimates.
This headline represents a significant corporate catalyst for Guardant Health. Better-than-expected sales and, more importantly, raised long-term guidance (FY26) indicate strong un…
Jul 30, 2026
Corporate Catalyst
Bullish
Impact 78
Guardant Health Raises FY2026 Sales Guidance from $1.300B-$1.320B to $1.340B-$1.360B vs $1.314B Est
Guardant Health (GH) has announced an upward revision to its fiscal year 2026 sales guidance, moving from $1.300 billion-$1.320 billion to $1.340 billion-$1.360 billion. This new r…
Jul 30, 2026
Corporate Catalyst
Bearish
Impact 92
Guardant Health Q2 Adj. EPS $(0.42) Misses $(0.41) Estimate, Sales $334.978M Beat $314.226M Estimate
Guardant Health's Q2 filing reveals a significant beat on sales, with revenue growing by 44.33% year-over-year, indicating strong demand for its products and services. However, the…
Jul 16, 2026
Corporate Catalyst
Bullish
Impact 55
Guggenheim Maintains Buy on Guardant Health, Raises Price Target to $190
Guggenheim analyst Subbu Nambi has maintained a 'Buy' rating on Guardant Health (GH) and raised the price target from $160 to $190. This action signals continued confidence in the …
Jul 14, 2026
Corporate Catalyst
Bullish
Impact 65
Canaccord Genuity Maintains Buy on Guardant Health, Raises Price Target to $205
This filing discloses that Canaccord Genuity analyst Kyle Mikson has raised the price target for Guardant Health (GH) from $135 to $205, while maintaining a 'Buy' rating. This sign…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.